204 related articles for article (PubMed ID: 21129837)
41. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
42. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
43. Error in body weight estimation leads to inadequate parenteral anticoagulation.
dos Reis Macedo LG; de Oliveira L; Pintão MC; Garcia AA; Pazin-Filho A
Am J Emerg Med; 2011 Jul; 29(6):613-7. PubMed ID: 20825842
[TBL] [Abstract][Full Text] [Related]
44. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement.
Meurin P; Tabet JY; Weber H; Renaud N; Ben Driss A
Circulation; 2006 Jan; 113(4):564-9. PubMed ID: 16449734
[TBL] [Abstract][Full Text] [Related]
45. 'Heparin rebound' means the opposite in cardiac surgery (bleeding) and in cardiology (thrombosis).
Koracevic G
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):198-9. PubMed ID: 20118712
[No Abstract] [Full Text] [Related]
46. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
47. [Recurrent thrombosis of a mitral mechanical heart valve prosthesis during puerperium--a case report].
Lisowska A; Prokop J; Hirnle T; Juszczyk G; Skibińska E; Musiał WJ; Klonowska-Dziatkiewicz E
Kardiol Pol; 2004 Jul; 61(7):49-51; discussion 52. PubMed ID: 15338018
[TBL] [Abstract][Full Text] [Related]
48. Differences in the safety profiles of two low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2008 Jun; 99(6):989-90. PubMed ID: 18521496
[No Abstract] [Full Text] [Related]
49. An unexpected complication of DVT prophylaxis.
Manktelow AR; Haddad FS; Powles DP
Acta Orthop Belg; 1997 Jun; 63(2):134-5. PubMed ID: 9265802
[TBL] [Abstract][Full Text] [Related]
50. [Low-molecular weight heparin in the treatment of pregnant women with high thrombotic risk].
Todorova K; Mazneĭkova V; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(4):46-52. PubMed ID: 15318544
[No Abstract] [Full Text] [Related]
51. Pellets for oral administration of low-molecular-weight heparin.
Scala-Bertola J; Gajdziok J; Rabisková M; Bonneaux F; Lecompte T; Sapin A; Maincent P
Drug Dev Ind Pharm; 2009 Dec; 35(12):1503-10. PubMed ID: 19929210
[TBL] [Abstract][Full Text] [Related]
52. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
Tapson VF
Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
[No Abstract] [Full Text] [Related]
53. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Papageorgiou A; Vassiliadis T; Giouleme O; Evgenidis N
Aliment Pharmacol Ther; 2006 May; 23(10):1443-53. PubMed ID: 16669959
[TBL] [Abstract][Full Text] [Related]
54. Occurrence and extent of bruising according to duration of administration of subcutaneous low-molecular-weight heparin: a quasi-experimental case-crossover study.
Palese A; Aidone E; Dante A; Pea F
J Cardiovasc Nurs; 2013; 28(5):473-82. PubMed ID: 22760174
[TBL] [Abstract][Full Text] [Related]
55. [Delayed hypersensitivity reaction due to subcutaneous sodium enoxaparin].
Ivanova I; Marco Segarra E; Agusti Corredor J; Pagés Reverter JM
Semergen; 2013; 39(1):59-60. PubMed ID: 23517900
[No Abstract] [Full Text] [Related]
56. Delayed hypersensitivity skin reaction to enoxaparin.
Méndez J; de la Fuente R; Stolle R; Vega JM; Sanchís ME; Armentia A; Sánchez P; Fernández A
Allergy; 1996 Nov; 51(11):853-4. PubMed ID: 8947349
[No Abstract] [Full Text] [Related]
57. A case of probable bemiparin-induced HIT type II managed with low-dose fondaparinux.
Koufakis T; Tsapakidis K; Margaritis A; Gabranis I
J Postgrad Med; 2015; 61(2):109. PubMed ID: 25766343
[No Abstract] [Full Text] [Related]
58. Delayed-type hypersensitivity reaction to enoxaparin in a pregnant woman.
Dabas G; De D; Handa S; Aggarwal D
Postgrad Med J; 2019 Sep; 95(1127):506. PubMed ID: 31431518
[No Abstract] [Full Text] [Related]
59. Acral hemorrhagic blisters induced by reviparin.
Pathania YS; Md AB
Int J Dermatol; 2019 Nov; 58(11):1329-1330. PubMed ID: 30843199
[No Abstract] [Full Text] [Related]
60. [ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage].
Einecke D
MMW Fortschr Med; 2011 Dec; 153(48):20. PubMed ID: 22299249
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
